Company cites strong commercial portfolio and R&D pipeline progress as it targets Q3 close for Crinetics acquisition.
Vertex Pharmaceuticals raised its 2026 revenue guidance to $13.1 billion-$13.2 billion, up from prior projections. The adjustment follows a strong Q2 performance and the planned acquisition of Crinetics Pharmaceuticals, expected to close in Q3 2026.
Management highlighted momentum in its commercial portfolio and rapid R&D pipeline progress. The Crinetics deal will add rare endocrine diseases as a fifth therapeutic focus area. Vertex previously reported $12.8 billion in 2025 revenue, with analysts expecting gradual growth.
No immediate market reaction was disclosed in the earnings call summary.